Evidence map›Paper›PMID 33123789›Full record

ArticleEuropean radiology2021

Predictive factors of severe abdominal pain during and after transarterial chemoembolization for hepatocellular carcinoma.

Atanas Pachev, Lucas Raynaud, Luisa Paulatto, Marco Dioguardi Burgio, Vincent Roche, Carmela Garcia Alba, Annie Sibert, Matthieu Lagadec, Juliette Kavafyan-Lasserre, Catherine Paugam-Burtz and 2 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Atanas PachevDepartment of Radiology, APHP.Nord, Hôpital Beaujon, Clichy, Hauts-de-Seine, France.
Lucas RaynaudDepartment of Radiology, APHP.Nord, Hôpital Beaujon, Clichy, Hauts-de-Seine, France.
Luisa PaulattoDepartment of Radiology, APHP.Nord, Hôpital Beaujon, Clichy, Hauts-de-Seine, France.
Marco Dioguardi BurgioDepartment of Radiology, APHP.Nord, Hôpital Beaujon, Clichy, Hauts-de-Seine, France.
Vincent RocheDepartment of Radiology, APHP.Nord, Hôpital Beaujon, Clichy, Hauts-de-Seine, France.
Carmela Garcia AlbaDepartment of Radiology, APHP.Nord, Hôpital Beaujon, Clichy, Hauts-de-Seine, France.
Annie SibertDepartment of Radiology, APHP.Nord, Hôpital Beaujon, Clichy, Hauts-de-Seine, France.
Matthieu LagadecDepartment of Radiology, APHP.Nord, Hôpital Beaujon, Clichy, Hauts-de-Seine, France.
Juliette Kavafyan-LasserreDepartment of Anaesthesiology, APHP.Nord, Hôpital Beaujon, Clichy, Hauts-de-Seine, France.
Catherine Paugam-BurtzUniversité de Paris, Paris, France.
Valérie VilgrainDepartment of Radiology, APHP.Nord, Hôpital Beaujon, Clichy, Hauts-de-Seine, France.
Maxime RonotDepartment of Radiology, APHP.Nord, Hôpital Beaujon, Clichy, Hauts-de-Seine, France. maxime.ronot@aphp.fr.ORCID http://orcid.org/0000-0001-7464-3939
Hôpital Beaujon · FRInserm · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo prospectively assess the frequency of severe abdominal pain during and after transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) using the visual analog scale (VAS), and to identify predictive factors.

methodsNinety-eight TACE performed in 80 patients (mean 65 ± 12 years old, 60 men) were consecutively and prospectively included. Abdominal pain was considered severe if the VAS ≥ 30/100 after treatment administration, or if opioid analgesic (grades 2-3) intake was required during hospitalization. Patient and tumor characteristics as well as technical factors associated with severe pain were identified by binary logistic regression.

resultsThe criterion for severe pain was met in 41/98 (42%) of procedures (peri-procedural pain 30/98 [31%] and opioid consumption during hospitalization 24/98 [25%]). Multivariate analysis identified age (odds ratio [OR] = 0.943 (95% confidence interval 0.895-0.994), p = 0.029), cirrhosis (OR = 0.284 (0.083-0.971), p = 0.045), and alcoholic liver disease (OR = 0.081 (0.010-0.659), p = 0.019) as negative predictive factors of severe abdominal pain. Severe abdominal pain occurred in or after 1/13 (8%), 8/34 (24%), 22/41 (54%), and 10/10 (100%) TACE sessions when none, one, two, and three of the protective factors were absent, respectively (p < 0.001). The area under the ROC curve of the combination of factors for the prediction of severe abdominal pain was 0.779 (CI 0.687-0.871).

conclusionSevere abdominal pain was frequent during and after TACE revealing a clinically relevant and underestimated problem. A predictive model based on three readily available clinical variables suggests that young patients without alcoholic liver disease or cirrhosis could benefit from reinforced analgesia. KEY POINTS: • Severe abdominal pain occurs in 43% of TACE for HCC. • Younger age, absence of cirrhosis, and absence of alcoholic liver disease were identified as independent predictive factors of severe abdominal pain. • A simple combination of the three abovementioned features helped predict the occurrence of severe abdominal pain.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsAbdominal PainAgedHumansMaleMiddle AgedRetrospective StudiesRisk FactorsTreatment OutcomeAnalgesics, opioidChemoembolization, therapeuticLiver cirrhosisPain, measurementPain, procedural

Identifiers

PMID33123789
OpenAlexW3096656198

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.